LGALS1 and post-transplant lymphoproliferative disease: For instance, Ouyang et al. showed that, in LCLs and EBV+ PTLD tumours, both gene products indirectly promoted apoptosis of EBV-specific CD8+ and CD4+ T cells through the transcriptional activation of immunomodulator Galectin-1 (Gal1) [90].